Core Viewpoint - The company has adjusted its 2024 annual profit distribution cash dividend total from CNY 222,585,426.80 to CNY 222,468,028.71 due to changes in total share capital resulting from the repurchase and cancellation of restricted stock options [1][2] Summary by Sections Adjustment of Profit Distribution - The cash dividend per share remains unchanged at CNY 0.17 (including tax) despite the total amount being adjusted [1] - The adjustment was necessary because the company repurchased and canceled 409,626 shares of restricted stock, affecting the total share capital [2] Pre-Adjustment Profit Distribution Plan - The initial profit distribution plan was based on a total share capital of 1,309,326,040 shares, with a proposed cash dividend of CNY 1.70 per 10 shares [1] - The total profit allocated for distribution was CNY 222,585,426.80, which exceeded 10% of the distributable profit and 30% of the net profit attributable to shareholders [1] Post-Adjustment Profit Distribution Plan - After the cancellation of shares, the total share capital decreased to 1,308,916,414 shares, leading to a new distribution base of 1,308,635,463 shares [4] - The adjusted total profit for distribution is now CNY 222,468,028.71, maintaining the cash dividend of CNY 1.70 per 10 shares [4] - The remaining distributable profit will be carried over to the next fiscal year [4]
南京医药: 南京医药关于调整2024年年度利润分配现金分红总额的公告